The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership
<p>Abstract</p> <p>Background</p> <p>Artemisinin-based combination therapy is currently recommended worldwide for the treatment of uncomplicated malaria. Fixed-dose combinations are preferred as they favour compliance. This paper reports on the initial phases of the pha...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-05-01
|
| Series: | Malaria Journal |
| Online Access: | http://www.malariajournal.com/content/10/1/142 |
| _version_ | 1811299521799389184 |
|---|---|
| author | Gaudin Karen Navaratnam Visweswaran Ghezzoul Bellabes Grislain Luc Terrassin Laurent Cuart Sylvie Fawaz Fawaz Caminiti Antonella Kiechel Jean-René Kauss Tina Lacaze Catherine White Nick J Olliaro Piero L Millet Pascal |
| author_facet | Gaudin Karen Navaratnam Visweswaran Ghezzoul Bellabes Grislain Luc Terrassin Laurent Cuart Sylvie Fawaz Fawaz Caminiti Antonella Kiechel Jean-René Kauss Tina Lacaze Catherine White Nick J Olliaro Piero L Millet Pascal |
| author_sort | Gaudin Karen |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Artemisinin-based combination therapy is currently recommended worldwide for the treatment of uncomplicated malaria. Fixed-dose combinations are preferred as they favour compliance. This paper reports on the initial phases of the pharmaceutical development of an artesunate-amodiaquine (ASAQ) bilayer co-formulation tablet, undertaken following pre-formulation studies by a network of scientists and industrials from institutions of both industrialized and low income countries.</p> <p>Methods</p> <p>Pharmaceutical development was performed by a research laboratory at the University Bordeaux Segalen, School of Pharmacy, for feasibility and early stability studies of various drug formulations, further transferred to a company specialized in pharmaceutical development, and then provided to another company for clinical batch manufacturing. The work was conducted by a regional public-private not-for-profit network (TropiVal) within a larger Public Private partnership (the FACT project), set up by WHO/TDR, Médecins Sans Frontières and the Drugs for Neglected Disease initiative (DND<it>i</it>).</p> <p>Results</p> <p>The main pharmaceutical goal was to combine in a solid oral form two incompatible active principles while preventing artesunate degradation under tropical conditions. Several options were attempted and failed to provide satisfactory stability results: incorporating artesunate in the external phase of the tablets, adding a pH regulator, alcoholic wet granulation, dry granulation, addition of an hydrophobic agent, tablet manufacturing in controlled conditions. However, long-term stability could be achieved, in experimental batches under GMP conditions, by physical separation of artesunate and amodiaquine in a bilayer co-formulation tablet in alu-alu blisters. Conduction of the workplan was monitored by DND<it>i</it>.</p> <p>Conclusions</p> <p>Collaborations between research and industrial groups greatly accelerated the process of development of the bi-layered ASAQ tablet. Lack of public funding was the main obstacle hampering the development process, and no intellectual property right was claimed. This approach resulted in a rapid technology transfer to the drug company Sanofi-Aventis, finalizing the process of development, registration and WHO pre-qualification of the fixed-dose co-formulation together with DND<it>i</it>. The bi-layered tablet is made available under the names of Coarsucam<sup>® </sup>and Artesunate amodiaquine Winthrop<sup>®</sup>, Sanofi-Aventis. The issue related to the difficulty of public institutions to valorise their participation in such initiative by lack of priority and funding of applied research is discussed.</p> |
| first_indexed | 2024-04-13T06:36:09Z |
| format | Article |
| id | doaj.art-0029bbadb03c4afa947da90105da0988 |
| institution | Directory Open Access Journal |
| issn | 1475-2875 |
| language | English |
| last_indexed | 2024-04-13T06:36:09Z |
| publishDate | 2011-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Malaria Journal |
| spelling | doaj.art-0029bbadb03c4afa947da90105da09882022-12-22T02:57:53ZengBMCMalaria Journal1475-28752011-05-0110114210.1186/1475-2875-10-142The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnershipGaudin KarenNavaratnam VisweswaranGhezzoul BellabesGrislain LucTerrassin LaurentCuart SylvieFawaz FawazCaminiti AntonellaKiechel Jean-RenéKauss TinaLacaze CatherineWhite Nick JOlliaro Piero LMillet Pascal<p>Abstract</p> <p>Background</p> <p>Artemisinin-based combination therapy is currently recommended worldwide for the treatment of uncomplicated malaria. Fixed-dose combinations are preferred as they favour compliance. This paper reports on the initial phases of the pharmaceutical development of an artesunate-amodiaquine (ASAQ) bilayer co-formulation tablet, undertaken following pre-formulation studies by a network of scientists and industrials from institutions of both industrialized and low income countries.</p> <p>Methods</p> <p>Pharmaceutical development was performed by a research laboratory at the University Bordeaux Segalen, School of Pharmacy, for feasibility and early stability studies of various drug formulations, further transferred to a company specialized in pharmaceutical development, and then provided to another company for clinical batch manufacturing. The work was conducted by a regional public-private not-for-profit network (TropiVal) within a larger Public Private partnership (the FACT project), set up by WHO/TDR, Médecins Sans Frontières and the Drugs for Neglected Disease initiative (DND<it>i</it>).</p> <p>Results</p> <p>The main pharmaceutical goal was to combine in a solid oral form two incompatible active principles while preventing artesunate degradation under tropical conditions. Several options were attempted and failed to provide satisfactory stability results: incorporating artesunate in the external phase of the tablets, adding a pH regulator, alcoholic wet granulation, dry granulation, addition of an hydrophobic agent, tablet manufacturing in controlled conditions. However, long-term stability could be achieved, in experimental batches under GMP conditions, by physical separation of artesunate and amodiaquine in a bilayer co-formulation tablet in alu-alu blisters. Conduction of the workplan was monitored by DND<it>i</it>.</p> <p>Conclusions</p> <p>Collaborations between research and industrial groups greatly accelerated the process of development of the bi-layered ASAQ tablet. Lack of public funding was the main obstacle hampering the development process, and no intellectual property right was claimed. This approach resulted in a rapid technology transfer to the drug company Sanofi-Aventis, finalizing the process of development, registration and WHO pre-qualification of the fixed-dose co-formulation together with DND<it>i</it>. The bi-layered tablet is made available under the names of Coarsucam<sup>® </sup>and Artesunate amodiaquine Winthrop<sup>®</sup>, Sanofi-Aventis. The issue related to the difficulty of public institutions to valorise their participation in such initiative by lack of priority and funding of applied research is discussed.</p>http://www.malariajournal.com/content/10/1/142 |
| spellingShingle | Gaudin Karen Navaratnam Visweswaran Ghezzoul Bellabes Grislain Luc Terrassin Laurent Cuart Sylvie Fawaz Fawaz Caminiti Antonella Kiechel Jean-René Kauss Tina Lacaze Catherine White Nick J Olliaro Piero L Millet Pascal The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership Malaria Journal |
| title | The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership |
| title_full | The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership |
| title_fullStr | The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership |
| title_full_unstemmed | The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership |
| title_short | The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership |
| title_sort | initial pharmaceutical development of an artesunate amodiaquine oral formulation for the treatment of malaria a public private partnership |
| url | http://www.malariajournal.com/content/10/1/142 |
| work_keys_str_mv | AT gaudinkaren theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT navaratnamvisweswaran theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT ghezzoulbellabes theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT grislainluc theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT terrassinlaurent theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT cuartsylvie theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT fawazfawaz theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT caminitiantonella theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT kiecheljeanrene theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT kausstina theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT lacazecatherine theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT whitenickj theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT olliaropierol theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT milletpascal theinitialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT gaudinkaren initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT navaratnamvisweswaran initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT ghezzoulbellabes initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT grislainluc initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT terrassinlaurent initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT cuartsylvie initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT fawazfawaz initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT caminitiantonella initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT kiecheljeanrene initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT kausstina initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT lacazecatherine initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT whitenickj initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT olliaropierol initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership AT milletpascal initialpharmaceuticaldevelopmentofanartesunateamodiaquineoralformulationforthetreatmentofmalariaapublicprivatepartnership |